Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

Sarcoma of the Uterus. Guideline of the DGGG and OEGGG (S2k Level, AWMF Register Number 015/074, February 2019).

Denschlag D, Ackermann S, Battista MJ, Cremer W, Egerer G, Follmann M, Haas H, Harter P, Hettmer S, Horn LC, Juhasz-Boess I, Kast K, Köhler G, Kröncke T, Lindel K, Mallmann P, Meyer-Steinacker R, Mustea A, Petru E, Reichardt P, Schmidt D, Strauss HG, Tempfer C, Thiel F, Ulrich U, Vogl T, Vordermark D, Gass P, Beckmann MW.

Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1043-1060. doi: 10.1055/a-0882-4116. Epub 2019 Oct 22.

2.

Potent cell cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, Phase 2 neoadjuvant study in HR+/HER2- breast cancer.

Hurvitz SA, Martín M, Press MF, Chan D, Fernandez-Abad M, Petru E, Rostorfer R, Guarneri V, Huang CS, Barriga S, Wijayawardana SR, Brahmachary M, Ebert PJ, Hossain A, Liu J, Abel A, Aggarwal A, Jansen VM, Slamon DJ.

Clin Cancer Res. 2019 Oct 15. pii: clincanres.1425.2019. doi: 10.1158/1078-0432.CCR-19-1425. [Epub ahead of print]

PMID:
31615937
3.

Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection.

Ulz P, Perakis S, Zhou Q, Moser T, Belic J, Lazzeri I, Wölfler A, Zebisch A, Gerger A, Pristauz G, Petru E, White B, Roberts CES, John JS, Schimek MG, Geigl JB, Bauernhofer T, Sill H, Bock C, Heitzer E, Speicher MR.

Nat Commun. 2019 Oct 11;10(1):4666. doi: 10.1038/s41467-019-12714-4.

4.

A rare case of cancer-to-cancer metastasis: breast cancer to renal cell cancer : Case report and review of literature.

Lakovschek IC, Petru E, Pollheimer MJ, Ratschek M, Augustin H, Bjelic-Radisic V.

Wien Med Wochenschr. 2019 Oct;169(13-14):350-353. doi: 10.1007/s10354-019-0694-y. Epub 2019 Apr 30. Review.

5.

Contralateral prophylactic mastectomy in women with breast cancer without a family history or genetic predisposition : Consensus statement from the Austrian Gynecologic Oncology Working Group of the Austrian Society of Obstetrics and Gynecology.

Bjelic-Radisic V, Singer C, Tamussino K, Kölbl H, Petru E, Volgger B, Polterauer S, Oppelt P, Sevelda P, Bogner G, Marth C; Austrian Gynecologic Oncology Working Group.

Wien Klin Wochenschr. 2019 May;131(9-10):233-236. doi: 10.1007/s00508-019-1468-7. Epub 2019 Mar 18.

PMID:
30887224
6.

Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) - Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities.

Emons G, Steiner E, Vordermark D, Uleer C, Bock N, Paradies K, Ortmann O, Aretz S, Mallmann P, Kurzeder C, Hagen V, van Oorschot B, Höcht S, Feyer P, Egerer G, Friedrich M, Cremer W, Prott FJ, Horn LC, Prömpeler H, Langrehr J, Leinung S, Beckmann MW, Kimmig R, Letsch A, Reinhardt M, Alt-Epping B, Kiesel L, Menke J, Gebhardt M, Steinke-Lange V, Rahner N, Lichtenegger W, Zeimet A, Hanf V, Weis J, Mueller M, Henscher U, Schmutzler RK, Meindl A, Hilpert F, Panke JE, Strnad V, Niehues C, Dauelsberg T, Niehoff P, Mayr D, Grab D, Kreißl M, Witteler R, Schorsch A, Mustea A, Petru E, Hübner J, Rose AD, Wight E, Tholen R, Bauerschmitz GJ, Fleisch M, Juhasz-Boess I, Lax S, Runnebaum I, Tempfer C, Nothacker MJ, Blödt S, Follmann M, Langer T, Raatz H, Wesselmann S, Erdogan S.

Geburtshilfe Frauenheilkd. 2018 Nov;78(11):1089-1109. doi: 10.1055/a-0715-2964. Epub 2018 Nov 26.

7.

Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project.

Cazzaniga ME, Munzone E, Bocci G, Afonso N, Gomez P, Langkjer S, Petru E, Pivot X, Sánchez Rovira P, Wysocki P, Torri V.

Adv Ther. 2019 Feb;36(2):381-406. doi: 10.1007/s12325-018-0844-4. Epub 2018 Dec 18.

PMID:
30565179
8.

Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).

Rinnerthaler G, Gampenrieder SP, Petzer A, Burgstaller S, Fuchs D, Rossmann D, Balic M, Egle D, Rumpold H, Singer CF, Bartsch R, Petru E, Melchardt T, Ulmer H, Mlineritsch B, Greil R.

BMC Cancer. 2018 Nov 6;18(1):1074. doi: 10.1186/s12885-018-4979-0.

9.

Comparison of Primary Tumor Size in Stage I and III Epithelial Ovarian Cancer.

Petru E, Huber C, Sampl E, Haas J.

Anticancer Res. 2018 Nov;38(11):6507-6511. doi: 10.21873/anticanres.13015.

PMID:
30396979
10.

Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) - Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer.

Emons G, Steiner E, Vordermark D, Uleer C, Bock N, Paradies K, Ortmann O, Aretz S, Mallmann P, Kurzeder C, Hagen V, van Oorschot B, Höcht S, Feyer P, Egerer G, Friedrich M, Cremer W, Prott FJ, Horn LC, Prömpeler H, Langrehr J, Leinung S, Beckmann MW, Kimmig R, Letsch A, Reinhardt M, Alt-Epping B, Kiesel L, Menke J, Gebhardt M, Steinke-Lange V, Rahner N, Lichtenegger W, Zeimet A, Hanf V, Weis J, Mueller M, Henscher U, Schmutzler RK, Meindl A, Hilpert F, Panke JE, Strnad V, Niehues C, Dauelsberg T, Niehoff P, Mayr D, Grab D, Kreißl M, Witteler R, Schorsch A, Mustea A, Petru E, Hübner J, Rose AD, Wight E, Tholen R, Bauerschmitz GJ, Fleisch M, Juhasz-Boess I, Sigurd L, Runnebaum I, Tempfer C, Nothacker MJ, Blödt S, Follmann M, Langer T, Raatz H, Wesselmann S, Erdogan S.

Geburtshilfe Frauenheilkd. 2018 Oct;78(10):949-971. doi: 10.1055/a-0713-1218. Epub 2018 Oct 19.

11.

Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy.

Friedlander M, Rau J, Lee CK, Meier W, Lesoin A, Kim JW, Poveda A, Buck M, Scambia G, Shimada M, Hilpert F, King MT, Debruyne P, Bologna A, Malander S, Monk BJ, Petru E, Calvert P, Herzog TJ, Barrett C, du Bois A.

Ann Oncol. 2018 Mar 1;29(3):737-743. doi: 10.1093/annonc/mdx796.

PMID:
29267856
12.

Prognostic role of plasma fibrinogen in patients with uterine leiomyosarcoma - a multicenter study.

Bekos C, Grimm C, Brodowicz T, Petru E, Hefler L, Reimer D, Koch H, Reinthaller A, Polterauer S, Polterauer M.

Sci Rep. 2017 Nov 3;7(1):14474. doi: 10.1038/s41598-017-13934-8.

13.

AGO Austria recommendation on screening and diagnosis of Lynch syndrome (LS).

Zeimet AG, Mori H, Petru E, Polterauer S, Reinthaller A, Schauer C, Scholl-Firon T, Singer C, Wimmer K, Zschocke J, Marth C.

Arch Gynecol Obstet. 2017 Jul;296(1):123-127. doi: 10.1007/s00404-017-4392-y. Epub 2017 May 16.

14.

Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.

Singer CF, Tan YY, Fitzal F, Steger GG, Egle D, Reiner A, Rudas M, Moinfar F, Gruber C, Petru E, Bartsch R, Tendl KA, Fuchs D, Seifert M, Exner R, Balic M, Bago-Horvath Z, Filipits M, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2017 Jul 15;23(14):3676-3683. doi: 10.1158/1078-0432.CCR-16-2373. Epub 2017 Jan 31.

15.

Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).

Sehouli J, Chekerov R, Reinthaller A, Richter R, Gonzalez-Martin A, Harter P, Woopen H, Petru E, Hanker LC, Keil E, Wimberger P, Klare P, Kurzeder C, Hilpert F, Belau AK, Zeimet A, Bover-Barcelo I, Canzler U, Mahner S, Meier W.

Ann Oncol. 2016 Dec;27(12):2236-2241. doi: 10.1093/annonc/mdw418. Epub 2016 Oct 26.

PMID:
27789470
16.

mFast-SeqS as a Monitoring and Pre-screening Tool for Tumor-Specific Aneuploidy in Plasma DNA.

Belic J, Koch M, Ulz P, Auer M, Gerhalter T, Mohan S, Fischereder K, Petru E, Bauernhofer T, Geigl JB, Speicher MR, Heitzer E.

Adv Exp Med Biol. 2016;924:147-155.

PMID:
27753036
17.

Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcoma.

Schwameis R, Grimm C, Brodowicz T, Petru E, Hefler-Frischmuth K, Staudigl C, Reinthaller A, Heinze G, Polterauer S, Polterauer M.

Sci Rep. 2016 Sep 20;6:33757. doi: 10.1038/srep33757.

18.

Inferring expressed genes by whole-genome sequencing of plasma DNA.

Ulz P, Thallinger GG, Auer M, Graf R, Kashofer K, Jahn SW, Abete L, Pristauz G, Petru E, Geigl JB, Heitzer E, Speicher MR.

Nat Genet. 2016 Oct;48(10):1273-8. doi: 10.1038/ng.3648. Epub 2016 Aug 29.

PMID:
27571261
19.

Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement.

Petru E, Singer CF, Polterauer S, Galid A, Schauer C, Klocker J, Seifert M, Reinthaller A, Benedicic C, Hubalek M, Hefler L, Marth C, Scholl-Firon T, Bogner G, Zeimet AG.

Wien Med Wochenschr. 2015 Oct;165(19-20):387-94. doi: 10.1007/s10354-015-0392-3. Epub 2015 Oct 15. Review.

PMID:
26471371
20.

The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine Leiomyosarcoma.

Schwameis R, Grimm C, Petru E, Natter C, Staudigl C, Lamm W, Koelbl H, Krainer M, Brodowicz T, Reinthaller A, Polterauer S.

PLoS One. 2015 Aug 6;10(8):e0133838. doi: 10.1371/journal.pone.0133838. eCollection 2015.

21.

AGO Austria recommendations for genetic testing of patients with ovarian cancer.

Marth C, Hubalek M, Petru E, Polterauer S, Reinthaller A, Schauer C, Scholl-Firon T, Singer CF, Zschocke J, Zeimet AG.

Wien Klin Wochenschr. 2015 Aug;127(15-16):652-4. doi: 10.1007/s00508-015-0814-7.

22.

Rapid Identification of Plasma DNA Samples with Increased ctDNA Levels by a Modified FAST-SeqS Approach.

Belic J, Koch M, Ulz P, Auer M, Gerhalter T, Mohan S, Fischereder K, Petru E, Bauernhofer T, Geigl JB, Speicher MR, Heitzer E.

Clin Chem. 2015 Jun;61(6):838-49. doi: 10.1373/clinchem.2014.234286. Epub 2015 Apr 20.

23.

Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.

Volgger B, Zeimet AG, Reinthaller A, Petru E, Schauer C, Klein M, Sevelda-Schwarzgruber U, Bogner G, Wolfram G, Marth C.

Int J Gynecol Cancer. 2015 Feb;25(2):257-62. doi: 10.1097/IGC.0000000000000352.

PMID:
25611899
24.

Has there been a change in peripartal maternal mortality in a tertiary care obstetric European center over the last five decades?

Mayer-Pickel K, Petru E, Mörtl M, Pickel H, Lang U.

Eur J Obstet Gynecol Reprod Biol. 2015 Feb;185:145-50. doi: 10.1016/j.ejogrb.2014.12.015. Epub 2014 Dec 29.

PMID:
25577555
25.

Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.

Pircher M, Mlineritsch B, Fridrik MA, Dittrich C, Lang A, Petru E, Weltermann A, Thaler J, Hufnagl C, Gampenrieder SP, Rinnerthaler G, Ressler S, Ulmer H, Greil R.

Anticancer Res. 2015 Jan;35(1):517-21.

PMID:
25550597
26.

Complete recovery of a wide local reaction by the use of dexrazoxane 72 hours after epirubicin extravasation: case report and review of the literature.

Aigner B, Bauernhofer T, Petru E, Niederkorn A, Arzberger EJ, Richtig E.

Dermatology. 2014;229(4):288-92. doi: 10.1159/000365391. Epub 2014 Nov 27. Review.

PMID:
25472626
27.

Molecular mechanisms of endometrial stromal sarcoma and undifferentiated endometrial sarcoma as premises for new therapeutic strategies.

Hrzenjak A, Dieber-Rotheneder M, Moinfar F, Petru E, Zatloukal K.

Cancer Lett. 2014 Nov 1;354(1):21-7. doi: 10.1016/j.canlet.2014.08.013. Epub 2014 Aug 13. Review.

PMID:
25128649
28.

The dynamic range of circulating tumor DNA in metastatic breast cancer.

Heidary M, Auer M, Ulz P, Heitzer E, Petru E, Gasch C, Riethdorf S, Mauermann O, Lafer I, Pristauz G, Lax S, Pantel K, Geigl JB, Speicher MR.

Breast Cancer Res. 2014 Aug 9;16(4):421. doi: 10.1186/s13058-014-0421-y.

29.

S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Wagner U, Harter P, Hilpert F, Mahner S, Reuß A, du Bois A, Petru E, Meier W, Ortner P, König K, Lindel K, Grab D, Piso P, Ortmann O, Runnebaum I, Pfisterer J, Lüftner D, Frickhofen N, Grünwald F, Maier BO, Diebold J, Hauptmann S, Kommoss F, Emons G, Radeleff B, Gebhardt M, Arnold N, Calaminus G, Weisse I, Weis J, Sehouli J, Fink D, Burges A, Hasenburg A, Eggert C.

Geburtshilfe Frauenheilkd. 2013 Sep;73(9):874-889. No abstract available.

30.

Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.

Smolle E, Taucher V, Petru E, Haybaeck J.

Anticancer Res. 2014 Apr;34(4):1519-30. Review.

PMID:
24692678
31.

Multiplex genetic cancer testing identifies pathogenic mutations in TP53 and CDH1 in a patient with bilateral breast and endometrial adenocarcinoma.

Heitzer E, Lax S, Lafer I, Müller SM, Pristauz G, Ulz P, Jahn S, Högenauer C, Petru E, Speicher MR, Geigl JB.

BMC Med Genet. 2013 Dec 29;14:129. doi: 10.1186/1471-2350-14-129.

32.

L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation.

Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA, Müller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M.

J Natl Cancer Inst. 2013 Aug 7;105(15):1142-50. doi: 10.1093/jnci/djt144. Epub 2013 Jun 18. Erratum in: J Natl Cancer Inst. 2013 Nov 20;105(22):1763.

PMID:
23781004
33.

Targeting signaling pathways in epithelial ovarian cancer.

Smolle E, Taucher V, Pichler M, Petru E, Lax S, Haybaeck J.

Int J Mol Sci. 2013 May 2;14(5):9536-55. doi: 10.3390/ijms14059536. Review.

34.

[Peripartum aortic dissection].

Pachler C, Knez I, Petru E, Dörfler O, Vicenzi M, Toller W.

Anaesthesist. 2013 Apr;62(4):293-5. doi: 10.1007/s00101-013-2153-2. Epub 2013 Mar 16. German.

PMID:
23494023
35.

Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer.

Heitzer E, Auer M, Hoffmann EM, Pichler M, Gasch C, Ulz P, Lax S, Waldispuehl-Geigl J, Mauermann O, Mohan S, Pristauz G, Lackner C, Höfler G, Eisner F, Petru E, Sill H, Samonigg H, Pantel K, Riethdorf S, Bauernhofer T, Geigl JB, Speicher MR.

Int J Cancer. 2013 Jul 15;133(2):346-56. doi: 10.1002/ijc.28030. Epub 2013 Feb 13.

36.

Treatment of Bone Metastases in Patients with Advanced Breast Cancer.

Gnant M, Balic M, Petru E, Raunik W, Singer CF, Steger GG, Watzke IM, Brodowicz T.

Breast Care (Basel). 2012 Apr;7(2):92-98. Epub 2012 Apr 24.

37.

Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer.

Petru E, Zeimet AG, Sevelda P, Seifert M, Singer C, Hubalek M, Angleitner-Boubenizek L, Speiser P, Benedicic C, Stummvoll W, Reinthaller A; Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO).

Wien Klin Wochenschr. 2012 Jun;124(11-12):412-8. doi: 10.1007/s00508-012-0185-2. Epub 2012 Jun 28. Erratum in: Wien Klin Wochenschr. 2012 Sep;124(17-18):669. Singer, Christian [added].

PMID:
22739650
38.

Conization of the uterine cervix: does the level of gynecologist's training predict margin status?

Ulrich D, Tamussino K, Petru E, Haas J, Reich O.

Int J Gynecol Pathol. 2012 Jul;31(4):382-6. doi: 10.1097/PGP.0b013e318242118c.

PMID:
22653354
39.

Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.

Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, Meier W, Bacon M, Maenpaa J, Petru E, Reed N, Gebski V, Pujade-Lauraine E, Lord S, Simes RJ, Friedlander M.

Br J Cancer. 2011 Jul 26;105(3):360-5. doi: 10.1038/bjc.2011.256. Epub 2011 Jul 12.

40.

Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.

Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E; Gynecologic Cancer Intergroup.

Ann Oncol. 2011 Nov;22(11):2417-23. doi: 10.1093/annonc/mdr001. Epub 2011 Mar 14.

PMID:
21402619
41.

Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.

Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, Hanker L, Pölcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A.

Int J Gynecol Cancer. 2011 Feb;21(2):289-95. doi: 10.1097/IGC.0b013e31820aaafd.

PMID:
21270612
42.

Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations.

Pristauz G, Petru E, Stacher E, Geigl JB, Schwarzbraun T, Tsybrovskyy O, Winter R, Moinfar F.

Histopathology. 2010 Dec;57(6):877-84. doi: 10.1111/j.1365-2559.2010.03724.x.

PMID:
21166701
43.

Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: results of an Austrian gynecologic oncologists' expert meeting.

Petru E, Reinthaller A, Angleitner-Boubenizek L, Schauer C, Zeimet A, Dirschlmayer W, Medl M, Stummvoll W, Sevelda P, Marth C.

Wien Klin Wochenschr. 2010 Nov;122(21-22):649-52. doi: 10.1007/s00508-010-1483-1. Epub 2010 Nov 15.

PMID:
21072604
44.

Fertility preservation and infertility treatment in breast cancer patients.

Petru E.

Wien Med Wochenschr. 2010 Nov;160(19-20):487-92. doi: 10.1007/s10354-010-0833-y. Epub 2010 Oct 26. Review.

PMID:
20972713
45.

[Effects of proteolytic enzyme therapy with Wobe Mugos against chemotherapy-induced toxicity in breast cancer patients - results of a pilot study].

Petru E, Stranz B, Petru C.

Wien Med Wochenschr. 2010 Nov;160(19-20):513-6. doi: 10.1007/s10354-010-0835-9. Epub 2010 Oct 26. German.

PMID:
20972712
46.

[Current aspects of breast carcinoma: 2].

Petru E.

Wien Med Wochenschr. 2010 Nov;160(19-20):477. doi: 10.1007/s10354-010-0837-7. German. No abstract available.

PMID:
20972710
47.

Prospective assessment of quality of life in long-term ovarian cancer survivors.

Greimel E, Daghofer F, Petru E.

Int J Cancer. 2011 Jun 15;128(12):3005-11. doi: 10.1002/ijc.25642. Epub 2010 Oct 26.

48.

[Hormonal contraception and breast cancer risk].

Bjelic-Radisic V, Petru E.

Wien Med Wochenschr. 2010 Nov;160(19-20):483-6. doi: 10.1007/s10354-010-0807-0. Epub 2010 Aug 16. Review. German.

PMID:
20714815
49.

Management of the placenta in advanced abdominal pregnancies at an East african tertiary referral center.

Oneko O, Petru E, Masenga G, Ulrich D, Obure J, Zeck W.

J Womens Health (Larchmt). 2010 Jul;19(7):1369-75. doi: 10.1089/jwh.2009.1704.

PMID:
20509789
50.

[BRCA1- and BRCA2 mutations: Clinical management of patients with hereditary breast and ovarian cancer].

Pristauz G, Geigl JB, Petru E.

Wien Med Wochenschr. 2010 Apr;160(7-8):158-62. doi: 10.1007/s10354-010-0772-7. Review. German.

PMID:
20473725

Supplemental Content

Support Center